Citation: | CHEN Yuqing, LI Jinming. Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 945-952. DOI: 10.12290/xhyxzz.2023-0139 |
[1] |
World Health Organization. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data[EB/OL].(2023-05-03)[2023-05-05]. https://covid19.who.int/?gclid=CjwKCAiAlNf-.
|
[2] |
World Health Organization. Tracking SARS-CoV-2 variants[EB/OL].(2023-04-27)[2023-05-05]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
|
[3] |
Vaughan A. Omicron emerges[J]. New Sci, 2021, 252: 7.
|
[4] |
Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness[J]. Nat Rev Microbiol, 2023, 21: 162-177.
|
[5] |
Hirose R, Itoh Y, Ikegaya H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: Both Omicron BA. 1 and BA. 2 have higher stability[J]. Clin Microbiol Infect, 2022, 28: 1486-1491. DOI: 10.1016/j.cmi.2022.05.020
|
[6] |
Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron[J]. Cell Mol Immunol, 2022, 19: 293-295. DOI: 10.1038/s41423-021-00836-z
|
[7] |
Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398: 2126-2128. DOI: 10.1016/S0140-6736(21)02758-6
|
[8] |
Pastorio C, Zech F, Noettger S. Determinants of spike infectivity, processing and neutralization in SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2[J]. Cell Host Microbe, 2022, 30: 1255-1268. DOI: 10.1016/j.chom.2022.07.006
|
[9] |
Chen J, Qiu Y, Wang R, et al. Persistent Laplacian projected Omicron BA. 4 and BA. 5 to become new dominating variants[J]. Comput Biol Med, 2022, 151: 106262. DOI: 10.1016/j.compbiomed.2022.106262
|
[10] |
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19: 141-154. DOI: 10.1038/s41579-020-00459-7
|
[11] |
Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94: 2376-2383. DOI: 10.1002/jmv.27643
|
[12] |
Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185: 467-484. e15. DOI: 10.1016/j.cell.2021.12.046
|
[13] |
Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1.529): infectivity, vaccine breakthrough, and antibody resistance[J]. J Chem Inf Model, 2022, 62: 412-422. DOI: 10.1021/acs.jcim.1c01451
|
[14] |
Chan YA, Zhan SH. The emergence of the spike furin cleavage site in SARS-CoV-2[J]. Mol Biol Evol, 2022, 39: msab327. DOI: 10.1093/molbev/msab327
|
[15] |
Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B. 1.1.7 and B. 1.351 variants to neutralizing antibodies[J]. Nat Med, 2021, 27: 917-924. DOI: 10.1038/s41591-021-01318-5
|
[16] |
Wang Q, Ye SB, Zhou ZJ, et al. Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization[J]. J Med Virol, 2023, 95: e28407. DOI: 10.1002/jmv.28407
|
[17] |
Cox MG, Peacock TP, Harvey WT, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies[J]. Nat Rev Microbiol, 2023, 21: 112-124. DOI: 10.1038/s41579-022-00809-7
|
[18] |
Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape[J]. Cell, 2021, 184: 2362-2371. e9. DOI: 10.1016/j.cell.2021.02.042
|
[19] |
Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants[J]. N Engl J Med, 2022, 386: 1579-1580. DOI: 10.1056/NEJMc2201849
|
[20] |
Rodino KG, Peaper DR, Kelly BJ, et al. Partial ORF1ab gene target failure with Omicron BA. 2.12.1[J]. J Clin Microbiol, 2022, 60: e00600-22.
|
[21] |
Cao Y, Yisimayi A, Jian F, et al. BA. 2.12.1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, 608: 593-602. DOI: 10.1038/s41586-022-04980-y
|
[22] |
Liu C, Lu J, Li P, et al. A Comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants[J]. Int J Infect Dis, 2023. doi: 10.1016/j.ijid.2023.01.039.
|
[23] |
Kumar S, Karuppanan K, Subramaniam G. Omicron (BA. 1) and sub-variants (BA. 1.1, BA. 2, and BA. 3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assess-ment[J]. J Med Virol, 2022, 94: 4780-4791. DOI: 10.1002/jmv.27927
|
[24] |
Fantini J, Yahi N, Colson P, et al. The puzzling mutational landscape of the SARS-CoV-2-variant Omicron[J]. J Med Virol, 2022, 94: 2019-2025. DOI: 10.1002/jmv.27577
|
[25] |
Fantini J, Yahi N, Azzaz F, et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks[J]. J Infect, 2021, 83: 197-206. DOI: 10.1016/j.jinf.2021.06.001
|
[26] |
Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608: 603-608. DOI: 10.1038/s41586-022-05053-w
|
[27] |
Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy[J]. J Infect, 2020, 81: e24-e27.
|
[28] |
Goldswain H, Dong X, Penrice-Randal R, et al. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection[J]. Genome Biol, 2023, 24: 47. DOI: 10.1186/s13059-023-02881-5
|
[29] |
Wu H, Xing N, Meng K, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2[J]. Cell Host Microbe, 2021, 29: 1788-1801. e6. DOI: 10.1016/j.chom.2021.11.005
|
[30] |
Garcia-Beltran WF, Denis KJS, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant[J]. Cell, 2022, 185: 457-466. e4. DOI: 10.1016/j.cell.2021.12.033
|
[31] |
Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells[J]. Emerg Microbes Infect, 2022, 11: 277-283. DOI: 10.1080/22221751.2021.2023329
|
[32] |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181: 271-280. e8. DOI: 10.1016/j.cell.2020.02.052
|
[33] |
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 2022, 603: 700-705. DOI: 10.1038/s41586-022-04462-1
|
[34] |
Shuai H, Chan JFW, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1.529 Omicron[J]. Nature, 2022, 603: 693-699. DOI: 10.1038/s41586-022-04442-5
|
[35] |
Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike[J]. Cell, 2022, 185: 2103-2115. e19. DOI: 10.1016/j.cell.2022.04.035
|
[36] |
Ito K, Piantham C, Nishiura H. Estimating relative generation times and relative reproduction numbers of Omicron BA. 1 and BA. 2 with respect to Delta in Denmark[J]. Math Biosci Eng, 2022, 19: 9005-9017. DOI: 10.3934/mbe.2022418
|
[37] |
Qassim SH, Chemaitelly H, Ayoub HH, et al. Effects of BA. 1/BA. 2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections[J]. J Travel Med, 2022, 29: taac068. DOI: 10.1093/jtm/taac068
|
[38] |
Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA. 4 and BA. 5[J]. Cell, 2022, 185: 3992-4007. e16. DOI: 10.1016/j.cell.2022.09.018
|
[39] |
Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 omicron lineages BA. 4 and BA. 5 in South Africa[J]. Nat Med, 2022, 28: 1785-1790. DOI: 10.1038/s41591-022-01911-2
|
[40] |
Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron(B. 1.1.529) and delta (B. 1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399: 1303-1312. DOI: 10.1016/S0140-6736(22)00462-7
|
[41] |
Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study[J]. Lancet Infect Dis, 2022, 22: 967-976. DOI: 10.1016/S1473-3099(22)00154-2
|
[42] |
Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399: 437-446. DOI: 10.1016/S0140-6736(22)00017-4
|
[43] |
Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron[J]. medRxiv[Preprint]. 2022. doi: 10.1101/2021.12.30.21268495.
|
[44] |
Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021[J]. Euro Surveill, 2021, 26: 2101146.
|
[45] |
Goga A, Bekker LG, Garrett N, et al. Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa[J]. Lancet, 2022, 400: 269-271. DOI: 10.1016/S0140-6736(22)01190-4
|
[46] |
Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1.529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California[J]. Nat Med, 2022, 28: 1933-1943. DOI: 10.1038/s41591-022-01887-z
|
[47] |
Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2022, 127: 63-68.
|
[48] |
Hui KPY, Ho JCW, Cheung M, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603: 715-720. DOI: 10.1038/s41586-022-04479-6
|
[49] |
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters[J]. Nature, 2022, 603: 687-692. DOI: 10.1038/s41586-022-04441-6
|
[50] |
Christie B. COVID-19: Early studies give hope omicron is milder than other variants[J]. BMJ, 2021, 375: n3144.
|
[51] |
Zhou H, Tada T, Dcosta BM, et al. Neutralization of SARS-CoV-2 Omicron BA. 2 by Therapeutic Monoclonal Antibodies[J]. bioRxiv[Preprint], 2022 Feb 24: 2022.02.15.480166.
|
[52] |
Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees[J]. Cell, 2022, 185: 2116-2131. e18. DOI: 10.1016/j.cell.2022.05.014
|
[53] |
Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA. 1, BA. 2, and BA. 3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J]. Nat Commun, 2022, 13: 3602. DOI: 10.1038/s41467-022-30681-1
|
[54] |
Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11: 337-343. DOI: 10.1080/22221751.2021.2022440
|
[55] |
Dupont L, Snell LB, Graham C, et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern[J]. Nat Microbiol, 2021, 6: 1433-1442. DOI: 10.1038/s41564-021-00974-0
|
[56] |
Zou J, Kurhade C, Xia H, et al. Cross-neutralization of Omicron BA. 1 against BA. 2 and BA. 3 SARS-CoV-2[J]. Nat Commun, 2022, 13: 2956. DOI: 10.1038/s41467-022-30580-5
|
[57] |
Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12.1, BA. 4, and BA. 5[J]. N Engl J Med, 2022, 387: 86-88. DOI: 10.1056/NEJMc2206576
|
[58] |
Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19[J]. Nat Rev Immunol, 2021, 21: 382-393. DOI: 10.1038/s41577-021-00542-x
|
[59] |
Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2[J]. Antiviral Res, 2022, 205: 105372. DOI: 10.1016/j.antiviral.2022.105372
|
[60] |
Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ. 1.1 and XBB[J]. N Engl J Med, 2023, 388: 89-91.
|
[61] |
Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA. 2.75.2, BQ. 1.1, and XBB from mRNA Bivalent Booster[J]. N Engl J Med, 2023, 388: 183-185. DOI: 10.1056/NEJMc2214293
|
[1] | ZHANG Han, GAO Yuan, MA Wanxin, LIU Hongxin, MENG Fanrui, ZHANG Danping, LIU Chunyu, LIU Lu, XING Ying. A Survey on the Mental Health Status of Social Workers Under Long-term Stress of COVID-19 and the Exploration of Associated Factors: A Case Study of Chaoyang District, Beijing[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 845-854. DOI: 10.12290/xhyxzz.2023-0588 |
[2] | CHE Lu, YU Jiawen, JIN Di, BAI Xue, WANG Yi, ZHANG Yuelun, XU Li, SHEN Le, HUANG Yuguang. Chronic Postsurgical Pain Among Patients with Preoperative COVID-19: An Ambispective Cohort Study[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 344-350. DOI: 10.12290/xhyxzz.2023-0556 |
[3] | LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281 |
[4] | ZHANG Kezhen, JIN Li. Research Progress of the Impact of SARS-CoV-2 on Fertility[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 953-958. DOI: 10.12290/xhyxzz.2023-0289 |
[5] | Multi-disciplinary Expert Team on Preoperative Evaluation and Timing of Surgery for Adult Patients After COVID-19 Infection, Peking Union Medical College Hospital. Preoperative Evaluation and Timing of Surgery for Adult Patients After COVID-19 Infection: Recommendations of Peking Union Medical College Hospital (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 266-270. DOI: 10.12290/xhyxzz.2023-0048 |
[6] | KANG Junren, YU kang, LIU Yanping, YAN Jie, DOU Pan, HUA Xin, Beijing Quality Control and Improvement Center for Clinical Nutrition Therapy. Recommendations of Nutritional Treatment for Patients with COVID-19 Infection (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 75-80. DOI: 10.12290/xhyxzz.2023-0019 |
[7] | LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697 |
[8] | ZENG Li'nan, ZHANG Lingli. Thinking about the Development of Rapid Recommendation Based on the Status of COVID-19 Evidence[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 544-551. DOI: 10.12290/xhyxzz.2021-0280 |
[9] | Wan-hong YIN, Yan KANG. Hemodynamic Therapy for COVID-19 Patients with Acute Respiratory Distress Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 518-521. DOI: 10.3969/j.issn.1674-9081.2020.05.004 |
[10] | Li LI, Li-na ZHANG, Chinese Critical Ultrasound Study Group. Lung Ultrasound and CT Assessment of Lung Injury in COVID-19: Which One is Better[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 514-517. DOI: 10.3969/j.issn.1674-9081.2020.05.003 |
1. |
庄丽,柯倩,郑菊,吴萍,蒋维佳. 2020—2023年贵州省新型冠状病毒基因进化特征分析. 中国公共卫生. 2024(05): 609-614 .
![]() | |
2. |
闫小龙,张眉,丁玉松,井明霞,李珂. SARS-CoV-2与流感病毒合并感染对患者预后影响meta分析. 中国公共卫生. 2023(12): 1563-1571 .
![]() |